[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [ACTIVE] · [BUSINESS]

2 clusters · 12 sources · 7 days · First seen · Last updated

Telix Pharmaceuticals financial performance and market value

Overview

Telix Pharmaceuticals Ltd experienced a significant share price decline on the ASX, falling between 6.6% and 8% following its third-quarter FY26 earnings announcement. Despite the drop, the company reported a 19% year-on-year revenue increase for the period ending September 30, bolstered by a 30% jump in its Precision Medicine business. Telix reaffirmed its fiscal 2026 revenue guidance, projecting total revenue and other income to exceed US$1 billion.

While the earnings results appeared to miss investor expectations, leading to initial volatility, market analysts have maintained a strong buy rating for the company. Brokers have identified potential upside, with an average target price suggesting a possible 103% increase over the next 12 months. This occurs amidst a broader recovery in the ASX 200 Healthcare Index.

Entities

Telix Pharmaceuticals Ltd · ASX · ASX 200 · S&P/ASX 200 · BHP Group

Timeline

  1. [BUSINESS] 11 sources
    Australia stock market rallies despite rising inflation

    Australian shares rose on tech and mining strength, but higher-than-expected inflation has increased bets on a Reserve Bank interest rate hike.

  2. [BUSINESS] 2 sources
    Telix Pharmaceuticals shares drop following third-quarter earnings

    Telix Pharmaceuticals shares fell on the ASX following its third-quarter FY26 results, despite reporting a 19% year-on-year revenue increase and reaffirming US$1 billion in annual revenue guidance.

Sources

communitynews.com.au · crypto-times.jp · finanzen.at · finanzen.ch · finnewsnetwork.com.au · fool.com.au · ibtimes.com.au · marketpress.jp · proactiveinvestors.co.uk · sharecafe.com.au · stockhead.com.au · tradingview.com